Evoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a report released on Monday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Down 0.6 %

Shares of NASDAQ:EVOK opened at $4.86 on Monday. Evoke Pharma has a 12-month low of $3.54 and a 12-month high of $13.80. The firm has a market capitalization of $7.22 million, a P/E ratio of -0.44 and a beta of 0.16. The firm has a fifty day moving average of $4.92 and a two-hundred day moving average of $5.23.

Institutional Investors Weigh In On Evoke Pharma

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. acquired a new stake in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned approximately 1.42% of Evoke Pharma as of its most recent filing with the Securities & Exchange Commission.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.